T-Bird Receives Authorization to Sell Medical Marijuana

T-Bird Pharma Inc. (TSXV:TPI) announced that Health Canada has confirmed the renewal of the production license for Thunderbird Biomedical Inc., its subsidiary. Health Canada has also expanded the company’s license to include “full authorization to commence medical marijuana sales.”

Dr. Bin Huang, president and CEO of T-Bird, commented:

We are very excited to have secured our sales license and look forward to begin servicing medical marijuana patients and executing on our patient acquisition and commercial roll out strategy. We can now begin providing Canadian patients with high quality medicinal marijuana. In addition to our ongoing commitment to scientific and clinical research, we have spent considerable time developing quality assurance and customer service systems that will be cornerstones of our commercialization effort. Securing a licence to sell represents a significant milestone in our Company’s evolution as we now move towards commercialization.

Click here to read the full T-Bird Pharma Inc. (TSXV:TPI) press release.